Literature DB >> 22541665

Pharmacotherapy of autism spectrum disorders.

Arianna Benvenuto1, Barbara Battan, Maria Cristina Porfirio, Paolo Curatolo.   

Abstract

Although no pharmacological or behavioral therapy has currently proven effective for treating all core symptoms of autism, many dysfunctional behaviors may be treated pharmacologically. Drug treatments should always be part of a comprehensive management plan that includes behavioral and educational interventions, and should be focused on specific targets. Several classes of psychotropic medications have been used to decrease the wide range of "maladaptive" or "interfering" behaviors and associated medical problems that can interfere with relationships and physical health and hinder the implementation of various non-pharmacological interventions. Atypical neuroleptics have been shown to be useful in the treatment of behavioral symptoms in autism. Attention deficit and hyperactivity disorder medications may be effective for counteracting the additional features of hyperactivity and short attention span. Antiepileptic drugs and selective serotonin reuptake inhibitors have shown promising results, but there are no specific indications for them as of yet. With respect to potential drug targets, some clinical features are caused by a dysfunction in neurochemical signaling systems, and thus may improve with selective pharmacological interventions acting on specific abnormal neurobiological pathways. Recent animal studies can be useful models for understanding the common pathogenic pathways leading to autism spectrum disorders (ASDs), and have the potential to offer new biologically focused treatment options.
Copyright © 2012 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22541665     DOI: 10.1016/j.braindev.2012.03.015

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  8 in total

1.  Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study.

Authors:  Marco Lamberti; Rosamaria Siracusano; Domenico Italiano; Norma Alosi; Francesca Cucinotta; Gabriella Di Rosa; Eva Germanò; Edoardo Spina; Antonella Gagliano
Journal:  Paediatr Drugs       Date:  2016-08       Impact factor: 3.022

2.  Adverse Events of Atomoxetine in a Double-Blind Placebo-Controlled Study in Children with Autism.

Authors:  Rameshwari V Tumuluru; Patricia Corbett-Dick; Michael G Aman; Tristram Smith; L Eugene Arnold; Xueliang Pan; Kristin A Buchan-Page; Nicole V Brown; Melissa M Ryan; Susan L Hyman; Jessica Hellings; Craig Williams; Jill A Hollway; Luc Lecavalier; Robert R Rice; Sarah McAuliffe-Bellin; Benjamin L Handen
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-05-16       Impact factor: 2.576

3.  Autism as the Early Closure of a Neuroplastic Critical Period Normally Seen in Adolescence.

Authors:  Julia Marie Berger; Troy T Rohn; Julia Thom Oxford
Journal:  Biol Syst Open Access       Date:  2013-08-20

4.  Neuroprotective potential of solanesol in intracerebroventricular propionic acid induced experimental model of autism: Insights from behavioral and biochemical evidence.

Authors:  Ramit Sharma; Saloni Rahi; Sidharth Mehan
Journal:  Toxicol Rep       Date:  2019-11-05

5.  Shared and Disorder-Specific Neurocomputational Mechanisms of Decision-Making in Autism Spectrum Disorder and Obsessive-Compulsive Disorder.

Authors:  Christina O Carlisi; Luke Norman; Clodagh M Murphy; Anastasia Christakou; Kaylita Chantiluke; Vincent Giampietro; Andrew Simmons; Michael Brammer; Declan G Murphy; David Mataix-Cols; Katya Rubia
Journal:  Cereb Cortex       Date:  2017-12-01       Impact factor: 5.357

6.  Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder.

Authors:  Sadeep Medhasi; Ekawat Pasomsub; Natchaya Vanwong; Nattawat Ngamsamut; Apichaya Puangpetch; Montri Chamnanphon; Yaowaluck Hongkaew; Penkhae Limsila; Darawan Pinthong; Chonlaphat Sukasem
Journal:  Neuropsychiatr Dis Treat       Date:  2016-04-13       Impact factor: 2.570

Review 7.  Aripiprazole for treating irritability in children & adolescents with autism: A systematic review.

Authors:  Ahmad Ghanizadeh; Sylvie Tordjman; Nematollah Jaafari
Journal:  Indian J Med Res       Date:  2015-09       Impact factor: 2.375

8.  Effect of prednisolone on language function in children with autistic spectrum disorder: a randomized clinical trial.

Authors:  Adriana Rocha Brito; Giselle de Paula Teixeira Vairo; Ana Paula Botelho Henriques Dias; Beni Olej; Osvaldo José Moreira Nascimento; Marcio Moacyr Vasconcelos
Journal:  J Pediatr (Rio J)       Date:  2020-04-22       Impact factor: 2.990

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.